Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response was written by Ramasamy, Karthik;Sadler, Ross;Jeans, Sally;Weeden, Paul;Varghese, Sherin;Turner, Alison;Larham, Jemma;Gray, Nathanael;Carty, Oluremi;Barrett, Joe;Bowcock, Stella;Oppermann, Udo;Cook, Gordon;Kyriakou, Chara;Drayson, Mark;Basu, Supratik;Moore, Sally;McDonald, Sarah;Gooding, Sarah;Javaid, Muhammad K.. And the article was included in British Journal of Haematology in 2022.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:
Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Using a prospective study of myeloma patients in the UK Rudy study cohort, we assessed humoral and interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration. We report data from 214 adults with myeloma (n = 204) or smoldering myeloma (n = 10) who provided blood samples at least three weeks after second vaccine dose. Pos. Anti-spike antibody levels (> 50 iu/mL) were detected in 189/203 (92.7%), pos. IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a neg. IGRA and neg. anti-spike protein antibody response. In all, 95/158 (60.1%) patients produced pos. results for both anti-spike protein serol. and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/anti-BCMA (B-cell maturation antigen) therapy and Pfizer-BioNTech vaccination. Further work is required to understand the clin. significance of divergent cellular response to vaccination. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.COA of Formula: C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem